CD8A and neoplasm: After treatment of prostate carcinoma patients with the FDA-approved Sipuleucel-T (a whole cell vaccine loaded with the fusion protein prostatic acid phosphatase and GM-CSF), decrease in the PSA serum level was positively correlated with an increased expression of Th1 (and CD8+) genes within tumor infiltrating T cells [133].